264 related articles for article (PubMed ID: 27845158)
1. The application of nanoparticles in diagnosis and theranostics of gastric cancer.
Li R; Liu B; Gao J
Cancer Lett; 2017 Feb; 386():123-130. PubMed ID: 27845158
[TBL] [Abstract][Full Text] [Related]
2. Cancer nanotheranostics: Strategies, promises and impediments.
Roy Chowdhury M; Schumann C; Bhakta-Guha D; Guha G
Biomed Pharmacother; 2016 Dec; 84():291-304. PubMed ID: 27665475
[TBL] [Abstract][Full Text] [Related]
3. Molecular Cancer Imaging with Polymeric Nanoassemblies: From Tumor Detection to Theranostics.
Mi P; Wang F; Nishiyama N; Cabral H
Macromol Biosci; 2017 Jan; 17(1):. PubMed ID: 27739631
[TBL] [Abstract][Full Text] [Related]
4. Next-generation nanotheranostics targeting cancer stem cells.
Reda A; Hosseiny S; El-Sherbiny IM
Nanomedicine (Lond); 2019 Sep; 14(18):2487-2514. PubMed ID: 31490100
[TBL] [Abstract][Full Text] [Related]
5. Metal nanoparticles: a theranostic nanotool against cancer.
Sharma H; Mishra PK; Talegaonkar S; Vaidya B
Drug Discov Today; 2015 Sep; 20(9):1143-51. PubMed ID: 26007605
[TBL] [Abstract][Full Text] [Related]
6. Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics.
Bose RJ; Paulmurugan R; Moon J; Lee SH; Park H
Drug Discov Today; 2018 Apr; 23(4):891-899. PubMed ID: 29426004
[TBL] [Abstract][Full Text] [Related]
7. Review of recent efforts to discover biomarkers for early detection, monitoring, prognosis, and prediction of treatment responses of patients with gastric cancer.
Sawaki K; Kanda M; Kodera Y
Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):657-670. PubMed ID: 29902383
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in aptamer-armed multimodal theranostic nanosystems for imaging and targeted therapy of cancer.
Vandghanooni S; Eskandani M; Barar J; Omidi Y
Eur J Pharm Sci; 2018 May; 117():301-312. PubMed ID: 29499349
[TBL] [Abstract][Full Text] [Related]
9. Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise.
Chen Q; Liu Z
Adv Mater; 2016 Dec; 28(47):10557-10566. PubMed ID: 27111654
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer.
Yang W; Ma J; Zhou W; Cao B; Zhou X; Yang Z; Zhang H; Zhao Q; Fan D; Hong L
Expert Opin Ther Targets; 2017 Nov; 21(11):1063-1075. PubMed ID: 28994330
[TBL] [Abstract][Full Text] [Related]
11. Oligonucleotide-based theranostic nanoparticles in cancer therapy.
Shahbazi R; Ozpolat B; Ulubayram K
Nanomedicine (Lond); 2016 May; 11(10):1287-308. PubMed ID: 27102380
[TBL] [Abstract][Full Text] [Related]
12. Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment.
Li K; Dan Z; Nie YQ
World J Gastroenterol; 2014 May; 20(18):5420-6. PubMed ID: 24833872
[TBL] [Abstract][Full Text] [Related]
13. Prussian blue nanoparticles and their analogues for application to cancer theranostics.
Patra CR
Nanomedicine (Lond); 2016 Mar; 11(6):569-72. PubMed ID: 26911239
[No Abstract] [Full Text] [Related]
14. Drug sensitivity testing platforms for gastric cancer diagnostics.
Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B
J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318
[TBL] [Abstract][Full Text] [Related]
15. Current and future biomarkers in gastric cancer.
Abbas M; Faggian A; Sintali DN; Khan GJ; Naeem S; Shi M; Dingding C
Biomed Pharmacother; 2018 Jul; 103():1688-1700. PubMed ID: 29864959
[TBL] [Abstract][Full Text] [Related]
16. Smart Cancer Cell Targeting Imaging and Drug Delivery System by Systematically Engineering Periodic Mesoporous Organosilica Nanoparticles.
Lu N; Tian Y; Tian W; Huang P; Liu Y; Tang Y; Wang C; Wang S; Su Y; Zhang Y; Pan J; Teng Z; Lu G
ACS Appl Mater Interfaces; 2016 Feb; 8(5):2985-93. PubMed ID: 26767305
[TBL] [Abstract][Full Text] [Related]
17. A challenge for theranostics: is the optimal particle for therapy also optimal for diagnostics?
Dreifuss T; Betzer O; Shilo M; Popovtzer A; Motiei M; Popovtzer R
Nanoscale; 2015 Oct; 7(37):15175-84. PubMed ID: 26313344
[TBL] [Abstract][Full Text] [Related]
18. Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer.
Ryu HS; Park DJ; Kim HH; Kim WH; Lee HS
Hum Pathol; 2012 Apr; 43(4):520-8. PubMed ID: 22018628
[TBL] [Abstract][Full Text] [Related]
19. Gastric Carcinoma: Recent Trends in Diagnostic Biomarkers and Molecular Targeted Therapies.
Majeed W; Iftikhar A; Khaliq T; Aslam B; Muzaffar H; Atta K; Mahmood A; Waris S
Asian Pac J Cancer Prev; 2016; 17(7):3053-60. PubMed ID: 27509928
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic molecular imaging of early gastric cancer using fluorescently labeled human H-ferritin nanoparticle.
Du Y; Fan K; Zhang H; Li L; Wang P; He J; Ding S; Yan X; Tian J
Nanomedicine; 2018 Oct; 14(7):2259-2270. PubMed ID: 30056091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
